Navigation Links
New Review on PROSTVAC(TM) Published by Key Investigators From NCI
Date:7/1/2009

KVISTGAARD, Denmark, July 1 /PRNewswire-FirstCall/ -- A just published Review in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009, confirms the previous published information on PROSTVAC(TM). This is the most comprehensive and updated Review on PROSTVAC(TM) so far.

Quote from the article: "Preliminary clinical trials have indicated negligible toxicity, and Phase II trials have suggested a survival benefit after treatment with PROSTVAC(TM), especially in patients with indolent disease characteristics."

Anders Hedegaard, President & CEO of Bavarian Nordic said: "We are very pleased that the scientific experts once again confirm their positive view on PROSTVAC(TM) and the potential use of the vaccine in earlier stages of the disease. We are looking forward to publish more data at a later stage."

Background information:

PROSTVAC(TM) is a therapeutic vaccine moving into late stage clinical development that has the potential to extend the lives of people with advanced prostate cancer. Administered subcutaneously, it induces a specific, targeted immune response that attacks prostate cancer cells. Conventional chemotherapy currently used to treat prostate cancer has limited survival rates and is often associated with numerous side effects. In contrast, PROSTVAC(TM) has the potential to extend survival with improved quality of life. PROSTVAC is being developed in collaboration with the National Cancer Institute under a Cooperative Research and Development Agreement with Bavarian Nordic's U.S.-based subsidiary, BN ImmunoTherapeutics.

In clinical trials to date PROSTVAC(TM) and related PSA containing poxviral vaccines have been investigated in more than 500 patients for 10 years.

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factor
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases
2. China Animal Welfare Law Under Review While 36,000 Dogs Culled
3. Advanced Life Sciences Announces Outcome of FDAs Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)
4. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
5. Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day
6. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
7. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
8. Savient Announces FDAs Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
9. ISTA Pharmaceuticals New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
10. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
11. Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... SYDNEY and SOUTHAMPTON , ... -- Australian pharmaceutical company Pharmaxis Ltd (ASX: PXS) and UK biotechnology ... into a research collaboration to develop a selective inhibitor to ... fatal lung disease idiopathic pulmonary fibrosis (IPF). ... US. Current products are expected to produce global revenues in ...
(Date:8/4/2015)... VIEW, Calif. , Aug. 4, 2015  IRIDEX ... James H. Mackaness , who had served as chief ... since 2012, has resigned his positions with the Company, ... officer position at another company. Mr. Mackaness intends to ... Company,s second quarter earnings announcement and 10-Q filing. ...
(Date:8/4/2015)...   Regulus Therapeutics Inc . (NASDAQ: ... and development of innovative medicines targeting microRNAs, today ... ended June 30, 2015 and provided a summary ... second quarter of 2015 and recent period marked ... Paul Grint, M.D., President and CEO of Regulus. ...
Breaking Medicine Technology:Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 2Pharmaxis and Synairgen Announce Research Collaboration to Develop LOXL2 Inhibitor For Pulmonary Fibrosis 3IRIDEX Chief Financial Officer Resigns to Accept Another Opportunity 2Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 2Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 3Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 4Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 5Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 6Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 7Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 8Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 9Regulus Reports Second Quarter 2015 Financial Results and Recent Highlights 10
... Reaffirms Primacy and Safety of ,First Generation, Antisense, ... (Nasdaq: GNTA ) announced the presentation of ... lead anticancer,compound, can be safely administered in high ... data were presented by Dr. Anthony Tolcher, Director,of ...
... - Studies Show Improvement in Hemodynamics and Delay ... Actelion Pharmaceuticals US, Inc.,today announced positive results from ... and effective as a combination therapy,for the treatment ... suggest that Tracleer, when given in combination with ...
Cached Medicine Technology:Genasense(R) Can be Administered by Brief High-Dose IV Infusion 2Genasense(R) Can be Administered by Brief High-Dose IV Infusion 3Genasense(R) Can be Administered by Brief High-Dose IV Infusion 4Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 2Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension 3
(Date:8/5/2015)... Baltimore (PRWEB) , ... August 05, 2015 , ... ... Nivel Siete, Remote-Learner and Blackboard’s open source companies (Moodlerooms, NetSpot and Remote-Learner UK) ... to formulate common standards and guidelines that will improve and streamline the process ...
(Date:8/5/2015)... ... , ... Jvion’s CEO, Shantanu Nigam , was named Readers’ choice: 21 ... designation is given to those leaders who are enabling innovation within healthcare IT. Shantanu ... firm’s clinical predictive analytic solutions. , A spokesperson for Jvion said, “Since our inception, ...
(Date:8/5/2015)... , ... August 05, 2015 , ... ... of $5.1 Billion by 2020, signifying a firm annualized growth of 11.7% between ... experiencing a steady growth due to increasing demand of ceramic membranes technologies and ...
(Date:8/5/2015)... ... , ... The June 6 opening of Chicago’s new elevated trail, the 606, has been getting ... a group of walkers at Sedgebrook senior living community in Lincolnshire. Known as the ... preserves and twice per month to more distant places. When they read about the ...
(Date:8/5/2015)... ... ... What language does a body speak? "Body Language – from Head to Toe" ... contain the name of a body part. , The use of body part-related expressions ... and expressions, for example, “back against the wall,” “brainstorming,” “sweet tooth,” and “tongue in ...
Breaking Medicine News(10 mins):Health News:Moodle Service Providers to Simplify Moodle Plugin Development 2Health News:Moodle Service Providers to Simplify Moodle Plugin Development 3Health News:Moodle Service Providers to Simplify Moodle Plugin Development 4Health News:Jvion’s Shantanu Nigam Named One of the 21 Health IT Leaders to Know 2Health News:Ceramic Membrane Market to Grow at a CAGR of 11.7% to 2020 2Health News:Ceramic Membrane Market to Grow at a CAGR of 11.7% to 2020 3Health News:Ceramic Membrane Market to Grow at a CAGR of 11.7% to 2020 4Health News:Ceramic Membrane Market to Grow at a CAGR of 11.7% to 2020 5Health News:Sedgebrook Trailblazers Tread New Ground on Chicago’s New 606 Path 2Health News:Sedgebrook Trailblazers Tread New Ground on Chicago’s New 606 Path 3Health News:Harvard Medical Professor Dr. Per-Olof Hasselgren Pens Unique Book Using Body Part Idioms 2
... Chico,s (NYSE: CHS ) is thrilled to ... the American Heart Association,s mission to prevent cardiovascular disease ... 2009, Chico,s committed to donate $2.82 from each sale ... Heart Association (AHA) in support of its Start! Movement, ...
... Month and groups across the country and around the globe ... awareness period. The purpose of Men,s Health Month is ... early detection and treatment of disease among men and boys. ... 15-21, the week ending on Father,s Day, a special awareness ...
... been babies, adults have crooned lullabies to soothe them. But ... suckle better and reduce their pain. , If confirmed, this ... babies feed on their own faster and move them out ... clinical professor in the Faculty of Medicine & Dentistry,s Department ...
... study is the first to show that there is ... disease in the general U.S. adult population. This work ... in highly-exposed chemical workers. The study is being presented ... ), the largest international gathering of physicians and researchers ...
... Orthodox Jewish School in Northeast Philadelphia , ... Philadelphia, ... largest medical assistance managed care organization in Pennsylvania, will hold a ... a new, safe playground at Politz Hebrew Academy, an Orthodox Jewish ...
... Advance Health Care Investment OpportunitiesCHICAGO, May 29 ... private equity firm focused exclusively on the health care ... to join the firm as a partner, effective July ... Mr. Womsley, 45, will work with Water Street,s team ...
Cached Medicine News:Health News:Chico's Raises $200K for the American Heart Association 2Health News:Join Men's Health Network in Celebration of Men's Health Month 2Health News:Join Men's Health Network in Celebration of Men's Health Month 3Health News:Music may improve feeding, reduce pain in premature babies: U of A study 2Health News:Environmental pollution increases the risk of liver disease 2Health News:Groundbreaking for Safe Playground Build at Politz Hebrew Academy 2Health News:Citi Private Equity Executive Joins Water Street Healthcare Partners 2Health News:Citi Private Equity Executive Joins Water Street Healthcare Partners 3
2-ply material consisting of polyethylene film inner layer and non-woven outer layers....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The cardiac blanket is pre-positioned at the waist during prep, unrolled upon closure of the saphenous vein graft incision, and inflated post-bypass....
The full access underbody blanket is positioned on the procedure table before the patient arrives to the room....
Medicine Products: